Nalidixic acid: Difference between revisions
m (Protected "Nalidixic acid": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 19: | Line 19: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Nalidixic acid''' is the basis for [[quinolone]] [[antibiotic]]s. | '''Nalidixic acid''' is the basis for [[quinolone]] [[antibiotic]]s. | ||
| Line 38: | Line 38: | ||
[[Category:Quinolone antibiotics]] | [[Category:Quinolone antibiotics]] | ||
[[de:Nalidixinsäure]] | [[de:Nalidixinsäure]] | ||
Revision as of 14:10, 20 August 2012
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 90% |
| Metabolism | Partially Hepatic |
| Elimination half-life | 6-7 hours, significantly longer in renal impairment |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C12H12N2O3 |
| Molar mass | 232.235 g/mol |
|
WikiDoc Resources for Nalidixic acid |
|
Articles |
|---|
|
Most recent articles on Nalidixic acid Most cited articles on Nalidixic acid |
|
Media |
|
Powerpoint slides on Nalidixic acid |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Nalidixic acid at Clinical Trials.gov Trial results on Nalidixic acid Clinical Trials on Nalidixic acid at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Nalidixic acid NICE Guidance on Nalidixic acid
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Nalidixic acid Discussion groups on Nalidixic acid Patient Handouts on Nalidixic acid Directions to Hospitals Treating Nalidixic acid Risk calculators and risk factors for Nalidixic acid
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Nalidixic acid |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Nalidixic acid is the basis for quinolone antibiotics.
Nalidixic acid is effective against both gram-positive and gram-negative bacteria. In lower concentrations, it acts bacteriostatically (that is, it inhibits growth and reproduction). In higher concentrations, it is bactericidal, meaning that it kills bacteria instead of merely inhibiting their growth.
It is especially used in treating urinary tract infections, caused for example by Escherichia coli, Proteus, Shigella, Enterobacter and Klebsiella.
External links
See also
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Quinolone antibiotics